Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape

DelveInsight's report highlights a robust DMD clinical trial pipeline with 70+ active players developing 75+ pipeline drugs. Key companies including Capricor, Solid Biosciences, Roche, Dyne Therapeutics, and BioMarin Pharmaceutical are advancing promising therapies targeting dystrophin expression and gene transfer. Approximately 6+ drugs are in late-stage development, with recent FDA designations granted to multiple candidates including AAV-SERCA2a and PBGENE-DMD, signaling strong momentum in addressing the high unmet need for disease-modifying DMD treatments.

05/26/2026, 1:00 PM • GlobeNewswire

Solid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services

U.S. Department of Health and Human Services added Duchenne muscular dystrophy to the Recommended Uniform Screening Panel, which is expected to accelerate early detection and improve patient outcomes.

12/16/2025, 4:51 PM • GlobeNewswire

Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia

Solid Biosciences received FDA Rare Pediatric Disease designation for SGT-212, a dual-route gene therapy targeting Friedreich's ataxia. The therapy aims to restore frataxin protein levels and address neurologic, cardiac, and systemic disease manifestations.

12/01/2025, 8:00 AM • GlobeNewswire

Solid Biosciences Announces Licensing Agreement with Andelyn Biosciences for the Use of Proprietary Next-Generation Capsid AAV-SLB101

Solid Biosciences has signed a non-exclusive worldwide license agreement with Andelyn Biosciences to provide access to its proprietary AAV-SLB101 gene therapy capsid, expanding collaborative efforts to over 30 agreements.

11/17/2025, 8:00 AM • GlobeNewswire

Solid Biosciences to Participate at Upcoming Investor Conferences

Solid Biosciences will participate in two healthcare investor conferences in November and December 2025, featuring presentations by its President/CEO and Chief Medical Officer, with live webcasts available.

11/11/2025, 8:00 AM • GlobeNewswire

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Solid Biosciences awarded 55,450 restricted stock units to four newly hired employees, with vesting over four years, under their 2024 Inducement Stock Incentive Plan.

08/01/2025, 8:00 AM • GlobeNewswire